×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BBOT – bridgebio oncology therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BBOT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
04:05 pm
bbot
BBOT to Participate in Upcoming December Investor Healthcare Conferences
Medium
Report
BBOT to Participate in Upcoming December Investor Healthcare Conferences
11/12
04:05 pm
bbot
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Low
Report
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
11/3
04:05 pm
bbot
BBOT to Participate in the Jefferies Global Healthcare Conference in London
Low
Report
BBOT to Participate in the Jefferies Global Healthcare Conference in London
10/30
05:45 pm
bbot
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
Low
Report
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
10/25
12:30 pm
bbot
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hypergly
Medium
Report
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hypergly
10/23
04:05 pm
bbot
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/13
04:05 pm
bbot
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Medium
Report
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/16
05:54 pm
bbot
Form 4 BridgeBio Oncology Thera For: Oct 10 Filed by: BridgeBio Pharma, Inc.
Low
Report
Form 4 BridgeBio Oncology Thera For: Oct 10 Filed by: BridgeBio Pharma, Inc.
10/6
04:22 pm
bbot
Form 4 BridgeBio Oncology Thera For: Oct 02 Filed by: Wallace Eli M.
Low
Report
Form 4 BridgeBio Oncology Thera For: Oct 02 Filed by: Wallace Eli M.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: